Press Releases September 1, 2026 04:05 PM

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Lexicon Pharmaceuticals schedules presentations at three major investor conferences in September 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
LXRX

Lexicon Pharmaceuticals, a biopharmaceutical company focused on developing transformative medicines, announced its management will present at three upcoming investor conferences in New York City during September 2026. The presentations will highlight the company's ongoing developments in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic, and other cardiometabolic indications.

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
LXRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Management presentations scheduled at Citi Biopharma, Cantor Global Healthcare, and H.C. Wainwright Investment Conferences in September 2026.
  • Company pipeline includes drug candidates targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and other cardiometabolic diseases.
  • Investor presentations accessible live and via replay on the company's website, increasing transparency and engagement.

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:

Citi 2026 Biopharma Back to School Conference
September 9, 2026, 11:20–11:55 AM (Eastern Time)

2026 Cantor Global Healthcare Conference
September 10, 2026, 3:20–3:50 PM (Eastern Time)

H.C. Wainwright 28th Annual Global Investment Conference
September 14, 2026, 9:00–9:30 AM (Eastern Time)

The live events and replays of the presentations can be accessed via the Events page on the company’s website at https://investors.lexpharma.com/.

About Lexicon Pharmaceuticals 
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com


Risks

  • No new clinical or financial data provided, so uncertainty remains regarding the progress and efficacy of pipeline drug candidates.
  • Investor reactions may depend on management’s disclosures during the upcoming presentations; lack of strong positive updates could limit market enthusiasm.
  • Biopharmaceutical sector remains subject to regulatory risks and competitive pressures affecting development timelines and market potential.

More from Press Releases

Skyworks Announces Extension of Expiration Date of Exchange Offers for Qorvo’s Senior Notes due 2029 and 2031 Sep 1, 2026 Quantumsphere Acquisition Corporation Announces Termination of the Agreement and Plan of Merger with SACH Pte. Ltd. Sep 1, 2026 Enovix’s TAA-Compliant Battery Manufacturing Strengthens Position with U.S. Defense Supply Chain Sep 1, 2026 Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange Sep 1, 2026 Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway Sep 1, 2026